{"schema_version":"secwatch.filing_event.v1","accession":"0001759138-26-000024","form_type":"8-K","ticker":"CABA","cik":"0001759138","company_name":"Cabaletta Bio, Inc.","filed_at":"2026-05-14T11:02:18+00:00","discovered_at":"2026-05-14T11:05:00.347530+00:00","generated_at":"2026-05-14T11:08:09.991518+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Cabaletta Bio presents preconditioning-free clinical data and automated manufacturing data for rese-cel at ASGCT 2026","bullets":["Two of four pemphigus vulgaris patients at lowest PC-free dose maintained drug-free responses through 6 months.","No dose-limiting toxicities or neurotoxicity; one patient had grade 1 cytokine release syndrome.","First two autoimmune patients dosed with rese-cel manufactured on Cell Shuttle met all release specs with similar PK/PD.","Higher-dose PC-free data expected 2H26; initial SLE data at lowest dose expected 1H26 at EULAR 2026 Congress."],"urls":{"canonical":"https://secwatch.observer/filing/0001759138-26-000024","json":"https://secwatch.observer/filing/0001759138-26-000024.json","markdown":"https://secwatch.observer/filing/0001759138-26-000024.md","text":"https://secwatch.observer/filing/0001759138-26-000024.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1759138/000175913826000024/0001759138-26-000024-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1759138/000175913826000024/caba-20260514.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud","generated_at":"2026-05-14T11:08:09.991518+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}